<DOC>
	<DOCNO>NCT01591447</DOCNO>
	<brief_summary>To determine safety efficacy single dose solithromycin ( CEM-101 ) treatment uncomplicated urogenital gonorrhea .</brief_summary>
	<brief_title>Safety Efficacy Study Single-Dose Oral CEM-101 Patients With Uncomplicated Urogenital Gonorrhea</brief_title>
	<detailed_description />
	<mesh_term>Gonorrhea</mesh_term>
	<criteria>1 . Evidence urogenital gonococcal infection ( prior culture , NAAT test , Gram stain , sexual contact ) 2 . Willing abstain anal , oral , vaginal sexual intercourse use condom study completion . 3 . Females childbearing potential ( include female less 2 year postmenopausal ) must negative pregnancy test enrollment . 1 . Confirmed , suspect , complicate systemic gonococcal infection pelvic inflammatory disease , arthritis , endocarditis . 2 . Known HIV , chronic hepatitis B , hepatitis C infection . 3 . Known concomitant infection would require additional systemic antibiotic . 4 . Use systemic intravaginal antibiotic within 30 day prior study drug administration . 5 . Current use corticosteroid drug immunosuppressive therapy . 6 . Cytotoxic chemotherapy radiation therapy within previous 3 month . 7 . Known significant renal , hepatic , hematologic impairment . 8 . History intolerance hypersensitivity macrolide antibiotic . 9 . Any concomitant condition , opinion Investigator , would preclude evaluation response make unlikely contemplated course therapy followup could complete ( e.g. , life expectancy &lt; 30 day ) .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>